Clinical Trial Update: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pasireotide lar in combination with everolimus for multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Everolimus (everolimus)
• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN